Beneficial ownership — 13D / 13G
87,387 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| Polar Asset Management Partners Inc. | BHAV BHAV Acquisition Corp | 13G | 7.8% | Mar 31, 2026 | 6mo |
| LMR Partners LLP | IPFX Inflection Point Acquisition Corp. VI | 13G | 6.7% | Mar 31, 2026 | 6mo |
| ARMISTICE CAPITAL, LLC | QTEX QTREX Quantum Ltd. | 13G | 9.99% | Mar 31, 2026 | 6mo |
| Alyeska Investment Group, L.P. | SKYX SKYX Platforms Corp. | 13G | 5.77% | Mar 31, 2026 | 6mo |
| HARRIS ASSOCIATES L P | MAS Masco Corp | 13G/A | 4.2% | Mar 31, 2026 | 6mo |
| Point72 Asset Management, L.P. | QTTB Q32 Bio Inc. | 13G/A | 5.7% | Mar 31, 2026 | 6mo |
| Carlyle Group Inc. | MDLN Medline Inc. | 13G/A | 20.6% | Mar 31, 2026 | 6mo |
| Pertento Partners LLP | NBBK NB Bancorp, Inc. | 13G/A | 4.6% | Mar 31, 2026 | 6mo |
| ORBIMED ADVISORS LLC | XLO Xilio Therapeutics, Inc. | 13G | 9.99% | Mar 31, 2026 | 6mo |
| TCG Crossover GP II, LLC | LBRX Lb Pharmaceuticals Inc | 13G/A | 6.4% | Mar 31, 2026 | 6mo |
| VIKING GLOBAL INVESTORS LP | ORIC Oric Pharmaceuticals, Inc. | 13G/A | 7.8% | Mar 31, 2026 | 6mo |
| Merus Global Investments, LLC | SVII Spring Valley Acquisition Corp. II Class A Ordinary Shares | 13G/A | 0% | Mar 31, 2026 | 6mo |
| T. Rowe Price Investment Management, Inc. | BELFA Bel Fuse Inc | 13G | 5.4% | Mar 31, 2026 | 6mo |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | EMPD Empery Digital Inc. | 13G | 9.9% | Mar 31, 2026 | 6mo |
| 4338618 Canada Inc. | DOO BRP Inc. | 13G/A | 29.69% | Mar 31, 2026 | 6mo |
| Stonepine Capital Management, LLC | QNRX Quoin Pharmaceuticals Ltd. | 13G/A | 9.99% | Mar 31, 2026 | 6mo |
| Point72 Asset Management, L.P. | ANAB Anaptysbio, Inc | 13G/A | 0.2% | Mar 31, 2026 | 6mo |
| SOFTBANK GROUP CORP. | LIFE Ethos Technologies Inc. | 13G | 10.1% | Mar 31, 2026 | 6mo |
| TANG CAPITAL MANAGEMENT LLC | VTYX Ventyx Biosciences, Inc. Common Stock | 13G/A | 0% | Mar 31, 2026 | 6mo |
| Polar Asset Management Partners Inc. | SSAC SPACSphere Acquisition Corp. | 13G | 8.2% | Mar 31, 2026 | 6mo |
| PRICE T ROWE ASSOCIATES INC /MD/ | FTI TechnipFMC plc | 13G/A | 7.8% | Mar 31, 2026 | 6mo |
| BAMCO INC /NY/ | IT Gartner Inc | 13G/A | 8.4% | Mar 31, 2026 | 6mo |
| Point72 Asset Management, L.P. | DNTH Dianthus Therapeutics, Inc. | 13G/A | 1.2% | Mar 31, 2026 | 6mo |
| WELLINGTON MANAGEMENT GROUP LLP | OCFC Oceanfirst Financial Corp | 13G/A | 4.5% | Mar 31, 2026 | 6mo |
| SOFTBANK GROUP CORP. | PAYP PayPay Corp | 13G | 90.7% | Mar 31, 2026 | 6mo |
| G1 Execution Services, LLC | WYNN Wynn Resorts Ltd | 13G | 5.1% | Mar 31, 2026 | 6mo |
| Nantahala Capital Management, LLC | IRLA IRulya Therapeutics Inc. | 13G/A | 7.52% | Mar 31, 2026 | 6mo |
| First Trust Capital Management L.P. | TONT Graf Global Corp. | 13G/A | 4.47% | Mar 31, 2026 | 6mo |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | ASBP Aspire-Lakewood Holdings, Inc. | 13G | 5.2% | Mar 31, 2026 | 6mo |
| Sculptor Capital LP | PALO Paloma Acquisition Corp I | 13G/A | 4.35% | Mar 31, 2026 | 6mo |
| PRICE T ROWE ASSOCIATES INC /MD/ | LAZ Lazard, Inc. | 13G/A | 8.6% | Mar 31, 2026 | 6mo |
| Manulife Investment Management (US) LLC | FWRG First Watch Restaurant Group, Inc. | 13G | 5.43% | Mar 31, 2026 | 6mo |
| Cormorant Asset Management, LP | ENGN enGene Therapeutics Inc. | 13G/A | 0% | Mar 31, 2026 | 6mo |
| LMR Partners LLP | PEW GrabAGun Digital Holdings Inc. | 13G/A | 7.9% | Mar 31, 2026 | 6mo |
| Alyeska Investment Group, L.P. | VELO Velo3D, Inc. | 13G/A | 0.84% | Mar 31, 2026 | 6mo |
| JANUS HENDERSON GROUP PLC | BHVN Biohaven Ltd. | 13G/A | 11.7% | Mar 31, 2026 | 6mo |
| Carlyle Group Inc. | SARO StandardAero, Inc. | 13G/A | 25.4% | Mar 31, 2026 | 6mo |
| Ikarian Capital, LLC | KPTIQ Karyopharm Therapeutics Inc. | 13G | 0% | Mar 31, 2026 | 6mo |
| Portolan Capital Management, LLC | VPG Vishay Precision Group, Inc. | 13G/A | 8.31% | Mar 31, 2026 | 6mo |
| RA CAPITAL MANAGEMENT, L.P. | RNA Atrium Therapeutics, Inc. | 13G | 5.6% | Mar 31, 2026 | 6mo |
| Redmile Group, LLC | IMNM Immunome Inc. | 13G/A | 4.9% | Mar 31, 2026 | 6mo |
| VAN ECK ASSOCIATES CORP | HMY Harmony Gold Mining Co Ltd | 13G/A | 5.25% | Mar 31, 2026 | 6mo |
| VAN ECK ASSOCIATES CORP | SMR NUSCALE POWER Corp | 13G | 6.3% | Mar 31, 2026 | 6mo |
| First Trust Capital Management L.P. | AAM AA Mission Acquisition Corp. | 13G/A | 0% | Mar 31, 2026 | 6mo |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | DRDB Roman DBDR Acquisition Corp. II | 13G | 7.5% | Mar 31, 2026 | 6mo |
| JANUS HENDERSON GROUP PLC | JBIO Jade Biosciences, Inc. | 13G/A | 6.3% | Mar 31, 2026 | 6mo |
| Encompass Capital Advisors LLC | FLOC Flowco Holdings Inc. | 13G/A | 3.13% | Mar 31, 2026 | 6mo |
| ARMISTICE CAPITAL, LLC | SQFT Presidio Property Trust, Inc. | 13G/A | 4.99% | Mar 31, 2026 | 6mo |
| AMERIPRISE FINANCIAL INC | GCMG GCM Grosvenor Inc. | 13G/A | 8.7% | Mar 31, 2026 | 6mo |
| EARNEST PARTNERS LLC | NSP Insperity, Inc. | 13G | 5.4% | Mar 31, 2026 | 6mo |